Selective demyelination of a sciatic nerve allograft after SARS-CoV-2 infection – Case report
Magdalena Koszewicz,
Dorota Kaminska,
Jacek Martynkiewicz,
Adam Domanasiewicz,
Jerzy Gosk
Affiliations
Magdalena Koszewicz
Department of Neurology, Wroclaw Medical University, Borowska 213, 50-556, Wroclaw, Poland; Corresponding author. Department of Neurology, Medical University of Wroclaw, Borowska 213, 50-556, Wroclaw, Poland.
Dorota Kaminska
Department of Trauma and Orthopedic Surgery, Regional Specialist Hospital, Kamienskiego 73a, 51-124, Wroclaw, Poland
Jacek Martynkiewicz
Department of Nephrology and Transplantation Medicine, Wroclaw Medical University, Borowska 213, 50-556, Wroclaw, Poland
Adam Domanasiewicz
Department of Trauma and Orthopedic Surgery, Regional Specialist Hospital, Kamienskiego 73a, 51-124, Wroclaw, Poland
Jerzy Gosk
Department of Biomedical Engineering, Faculty of Fundamental Problems of Technology, Wroclaw University of Science and Technology, Grunwaldzki Sq. 13 (D-1), 50-377, Wroclaw, Poland
Peripheral neurological complications are seen after SARS-CoV-2 infections. These are mostly immune-mediated such as Guillaine–Barré syndrome or chronic inflammatory demyelinating polyneuropathy. We present a 39-year-old man treated with a right sciatic nerve allotransplantation with subsequent clinical and electrophysiological improvement within 30 months of observation. After SARS-CoV-2 infection, he developed clinical deterioration with selective sciatic nerve demyelination in a nerve conduction study. Nerve conduction velocity returned to previous values within six months of treatment. Intravenous immunoglobulins were used at standard dosage. The inflammatory immune process seemed to be a cause of peripheral demyelination isolated to a nerve allograft with good reaction for intravenous immunoglobulin treatment.
